Page 1

Press Release GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business • • • • Updates € 6.5 million collected from paid early access programs ; after recognition of rebates and a € 4.3 million non - cash change in accounting estimate , reported IFRS revenue amounted to € ( 1.2 ) million . Net cash used in operating activities was reduced by 37 % to € 1.6 million . GS010 / LUMEVOQⓇ manufacturing technology transfer to Catalent successfully completed ; manufacturing of a new GMP batch for early access programs has started . REVISE dose - ranging study is on track , with the last patient scheduled for December 2026 . - Paris , France , Tuesday , September 29 , 2026 , 10:30 pm CEST – GenSight Biologics ( Euronext : SIGHT , ISIN : FR0013183985 , PEA - PME eligible ) , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders , today reported its interim financial results for the first half of 2026 and provided business updates . The 2026 half - year condensed consolidated financial statements were subject to a limited review by the Company's statutory auditors and approved by the Board of Directors on September 29 , 2026. The statutory auditors ' review report includes an emphasis of matter paragraph drawing attention to the material uncertainty related to going concern described in Note 3.4 of the condensed consolidated financial statements . The full half - year financial report will be available on the Company's website in the Investors section . " The first half of 2026 marked a turning point for GenSight : for the first time since 2022 , patients received GS010 / LUMEVOQⓇ under authorized paid early access programs , and as a result , we collected € 6.5 million over the period , " noted Jan Eryk Umiastowski , Chief Financial Officer of GenSight Biologics . " The negative revenue reported for the first half reflects future rebates and a one - off non - cash change in accounting estimate and so does not capture the stronger cash collection the company actually achieved . Early access revenues enabled us to reduce our operating cash burn by 37 % to € 1.6 million in the first half . With the successful transfer of our manufacturing process to Catalent , our priority now is to secure the structural financing for the RECOVER Phase III trial . ” Business Updates Manufacturing The technology transfer to Catalent has been completed , with both the upstream and downstream stages successful . As announced on September 8 , 2026 , the viral genome ( vg ) titer of the engineering batch drug substance was within target specifications , and its reproducibility indicated that the transferred process would have repeatable yields . The full battery of drug substance test results , received at the end of the summer , has now confirmed the successful transfer of the process . Manufacturing of a new GMP batch to sustain product supply for the Company's early access programs has started.1 This manufacturing run is expected to be completed in January 2027 , with full release of the drug product batch expected in March 2027 . GS010 / LUMEVOQⓇ is an investigational gene therapy that has not received marketing authorization in any country .